776 Thermo Fisher Scientific Inc. $TMO Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,385 shares of the medical research company’s stock after selling 776 shares during the period. Illinois Municipal Retirement Fund’s holdings in Thermo Fisher Scientific were worth $2,960,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Compass Financial Management LLC boosted its stake in Thermo Fisher Scientific by 137.5% in the third quarter. Compass Financial Management LLC now owns 38 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 22 shares during the last quarter. Polaris Financial Partners bought a new stake in Thermo Fisher Scientific in the third quarter valued at about $32,000. Laurel Wealth Advisors LLC acquired a new position in Thermo Fisher Scientific in the third quarter valued at about $32,000. Kilter Group LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at about $25,000. Finally, Legacy Wealth Managment LLC ID boosted its holdings in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, VP Lisa Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc Casper sold 10,000 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,546 shares of company stock valued at $15,479,192 over the last three months. 0.33% of the stock is owned by company insiders.

Analysts Set New Price Targets

TMO has been the topic of several recent analyst reports. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating and lifted their price objective for the company from $660.00 to $690.00 in a report on Tuesday, September 1st. Argus boosted their price objective on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the company a “buy” rating in a research report on Friday, October 30th. DZ Bank cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Sanford C. Bernstein upped their price target on Thermo Fisher Scientific from $520.00 to $575.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Finally, CLSA started coverage on shares of Thermo Fisher Scientific in a report on Thursday, September 3rd. They issued an “outperform” rating and a C$748.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $683.64.

Key Thermo Fisher Scientific News

These are some of the TMO news items that stood out recently:

• Positive Sentiment: A Sound Shore Management investor letter describes Thermo Fisher as near a cyclical bottom, with potential to re-accelerate toward historical growth. That outlook may support sentiment, though it is an investor’s assessment rather than company guidance. Article: Thermo Fisher Scientific cyclical bottom signals re-acceleration
• Neutral Sentiment: CEO Marc Casper is scheduled to join a UBS fireside chat on November 19. Investors may listen for business commentary, but the announcement itself contains no new financial or operational information. Article: UBS CEO Call Series
• Neutral Sentiment: A recent analysis revisits Thermo Fisher’s $5 billion buyback and cash generation after strong multiyear share gains. The buyback supports capital returns, while the discussion highlights the need for future cash flows to justify expectations; the article excerpt gives no new buyback details or firm valuation conclusion. Article: Is Thermo Fisher reasonable after its $5 billion buyback?

Thermo Fisher Scientific Stock Up 0.1%

TMO traded up $0.54 on Friday, hitting $699.98. 1,837,337 shares of the company were exchanged, compared to its average volume of 2,259,394. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $727.56. The company has a market cap of $259.36 billion, a PE ratio of 36.92, a PEG ratio of 2.85 and a beta of 0.84. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The stock’s fifty day moving average is $670.82 and its 200-day moving average is $556.81.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. The firm had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company earned $5.79 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.27 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Tuesday, December 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.92%.

About Thermo Fisher Scientific

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.